Growth hormone and the heart.
Impaired cardiovascular function has recently been demonstrated to potentially reduce life expectancy both in GH deficiency and excess. Experimental and clinical studies have supported the evidence that GH and IGF-I are implicated in cardiac development. In most patients with acromegaly a specific cardiomyopathy, characterized by myocardial hypertrophy with interstitial fibrosis, lympho-mononuclear infiltration and areas of monocyte necrosis, results in biventricular concentric hypertrophy. In contrast, patients with childhood or adulthood-onset GH deficiency (GHD) may suffer both from structural cardiac abnormalities, such as narrowing of cardiac walls, and functional impairment, that combine to reduce diastolic filling and impair left ventricular response to peak exercise. In addition, GHD patients may have an increase in vascular intima-media thickness and a higher occurrence of atheromatous plaques, that can further aggravate the haemodynamic conditions and contribute to increased cardiovascular and cerebrovascular risk. However, several lines of evidence have suggested that the cardiovascular abnormalities can be partially reversed by suppressing GH and IGF-I levels in acromegaly or after GH replacement therapy in GHD patients. Recently, much attention has been focussed on the ability of GH to increase cardiac mass suggesting its possible use in the treatment of chronic nonendocrine heart failure. In fact, GH administration can induce an improvement in haemodynamic and clinical status in some patients. Although these data need to be confirmed in more extensive studies, such promising results seem to open new perspectives for GH treatment in humans.
Colao
A
A
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy. colao@unina.it
Marzullo
P
P
Di Somma
C
C
Lombardi
G
G
D000172:Acromegaly / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D000328:Adult; D000818:Animals; D016022:Case-Control Studies; D002648:Child; D005260:Female; D013006:Growth Hormone / Q000172:deficiency / Q000502:physiology* / Q000627:therapeutic use; D006321:Heart / Q000502:physiology* / Q000503:physiopathology; D006331:Heart Diseases / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D006439:Hemodynamics; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000502:physiology; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use; D009842:Oligopeptides / Q000627:therapeutic use; D051381:Rats; D013318:Stroke Volume / Q000187:drug effects
D006728:Hormones; D009842:Oligopeptides; C086184:hexarelin; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D015282:Octreotide